Abstract: A bed has a mattress. One or more sensors are configured to sense one or more physical phenomena of a sleeper on the bed and generate data signals based on the sensed physical phenomena; and send, to a computing system, the data signals. A computing system comprising one or more processors and computer memory. The computing system is configured to: receive the data signals; generate, from data signals of a sleep-session of the sleeper, a feature vector of features, each feature having a feature value that represents one of the physical phenomena; and classify the sleeper into a classified physical state of long COVID for the sleep session based on the feature vector.

Abstract: The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1 (7-37), GLP-1 (7-37) analogs (e.g., GLP-1 (7-36)-NH2) and the like. The GLP-1 receptor agonist compound may be exenatide.

Abstract: The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1 (7-37), GLP-1 (7-37) analogs (e.g., GLP-1 (7-36)-NH2) and the like. The GLP-1 receptor agonist compound may be exenatide.

Abstract: The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs (e.g., GLP-1(7-36)-NH2) and the like. The GLP-1 receptor agonist compound may be exenatide.

Abstract: The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1(7-37), GLP-1 (7-37) analogs (e.g., GLP-1 (7-36)-NH2) and th like. The GLP-1 receptor agonist compound may be exenatide.

Abstract: Methods for re-establishing normal sleep patterns in adults with age-related sleep disorders are provided. In particular, methods are disclosed wherein a compound that stimulates growth hormone and/or prolactin secretion is orally administered to subjects just prior to retiring.

Abstract: A method for sleep quality is disclosed comprising administering an effective amount of N-[1(R)-[(1,2-dihydro-1-methanesulfonylspiro-(3H-indole-3,4'-piperidin)-1' -yl)carbonyl]-2-(phenylmethoxy)-ethyl]-2-amino-2-methylpropanamide methansulfonate.

Abstract: Methods for reestablishing normal nocturnal growth hormone and prolactin secretion in adults with low slow-wave (deep) sleep are provided. In particular, methods are disclosed where .gamma.-hydroxybutyrate is orally administered to subjects just prior to retiring.